Form 4: Director Richard Pops Receives NBIX Equity Grant

Neurocrine Biosciences Director Richard Pops was granted 2,567 restricted stock units vesting in May 2027.

Summary

• Director Richard Pops received an equity grant of 2,567 Restricted Stock Units (RSUs) from Neurocrine Biosciences.
• Each RSU represents the right to receive one share of common stock upon vesting.
• The grant is scheduled to vest in full on May 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified in this filing.

Risks

• Standard market risks associated with equity ownership and potential share price volatility.

Future Outlook

The RSUs are subject to a one-year vesting period, concluding on May 27, 2027.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for mid-to-large cap biotechnology firms.
• The one-year cliff vesting schedule is a common retention and incentive structure for board members.

Stakeholder Impact

• Minimal impact on shareholders as this represents standard director compensation.

Next Steps

• Vesting of the 2,567 RSUs on May 27, 2027.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Equity Compensation, Director Compensation